Life Extension Final Clerance Sale

Acetaminophen and NSAID Toxicity References

Disease Prevention and Treatment, 5th edition

The references on this page correspond with the print version of Disease Prevention and Treatment, 5th edition. Since we continuously update the protocols online in response to new scientific developments, readers are encouraged to review the latest versions of the protocols.

  1. Conaghan PG. A turbulent decade for NSAIDs: update on current concepts of classification, epidemiology, comparative efficacy, and toxicity. Rheumatol Int. 2012;32(6):1491–502.
  2. Goldman L. Goldman's Cecil Medicine, 24th ed. Copyright © 2011 Saunders, An Imprint of Elsevier. Available at: http://www.mdconsult.com/books/page.do?eid=4-u1.0-B978-1-4377-1604-7..C2009-0-42832-0&isbn=978-1-4377-1604-7&uniqId=345936036-9#4-u1.0-B978-1-4377-1604-7..C2009-0-42832-0--TOP Accessed 7/17/2012.
  3. Mayo Clinic.Arthritis. Updated 1/22/2011. Available at: http://www.mayoclinic.com/health/arthritis/DS01122/DSECTION=treatments-and-drugs Accessed 7/17/2012.
  4. Amar PJ and Schiff ER. Acetaminophen safety and hepatotoxicity--where do we go from here? Expert Opin Drug Saf. 2007;6(4):341–55.
  5. Harvard Medical School. 12 things you should know about pain relievers. 2006. Available at: http://www.health.harvard.edu/fhg/updates/12-things-you-should-know-about-pain-relievers.shtml. Accessed 7/17/2012.
  6. Larson AM, Polson J, Fontana RJ, et al. Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. Hepatology. 2005;42(6):1364–72.
  7. Craig DGN, Ford AC, Hayes PC, et al. Systematic review: prognostic tests of paracetamol-induced acute liver failure. Aliment PharmacolTher. 2010;31(10):1064–76.
  8. Bessems JG and Vermeulen NP.Paracetamol (acetaminophen)-induced toxicity: molecular and biochemical mechanisms, analogues and protective approaches. Crit Rev Toxicol. 2001;31(1):55–138.
  9. Watkins PB, Kaplowitz N, Slattery JT, et al. Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily: a randomized controlled trial. JAMA. 2006;296(1):87–93.
  10. Sharma M. Chronic Acetaminophen Toxicity. 10/26/2009. Available at: http://lib.sh.lsuhsc.edu/am_rpt/media/files/10232009.pdf Accessed 7/18/2011.
  11. Van Mil AH, and Janssens AR. [Acetaminophen use by chronic alcohol abusers: a therapeutic dose may be too much for the liver]. Ned TijdschrGeneeskd. 2001 Sep 29;145(39):1873-6.
  12. Singh G. Recent considerations in nonsteroidal anti-inflammatory drug gastropathy. Am. J. Med. 1998;105(1B):31S–38S
  13. Vonkeman HE and van de Laar MAFJ.Nonsteroidal anti-inflammatory drugs: adverse effects and their prevention. Semin Arthritis Rheum. 2010;39(4):294–312.
  14. Trelle S, Reichenbach S, Wandal S, et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ. 2011;342:c7086.
  15. Back M, Yin L, Ingelsson E. Cyclooxygenase-2 inhibitors and cardiovascular risk in a nation-wide cohort study after the withdrawal of rofecoxib. Eur Heart J. 2011 Nov 21. [Epub ahead of print]
  16. Moodley I. Review of the cardiovascular safety of COXIBs compared to NSAIDS. Cardiovasc J Afr. 2008 Mar-Apr;19(2):102-7.
  17. Ejaz P, Bhojani K, Joshi VR. NSAIDs and kidney.J Assoc Physicians India. 2004 Aug;52:632-40.
  18. Ferner RE, Dear JW, Bateman DN. Management of paracetamol poisoning.BMJ. 2011;342:d2218.
  19. Vestergaard P, Hermann P, Jensen JEB, et al. Effects of paracetamol, non-steroidal anti-inflammatory drugs, acetylsalicylic acid, and opioids on bone mineral density and risk of fracture: results of the Danish Osteoporosis Prevention Study (DOPS). Osteoporos Int. 2012;23(4):1255–65.
  20. Kristensen, DM, Hass, U, Lesné, L, et al. Intrauterine exposure to mild analgesics is a risk factor for development of male reproductive disorders in human and rat. Hum. Reprod. 2011;26(1):235–44
  21. Kristensen DM, Lesné L, Le Fol V, et al. Paracetamol (acetaminophen), aspirin (acetylsalicylic acid) and indomethacin are anti-androgenic in the rat foetal testis. Int J Androl. 2012;35(3):377–84.
  22. Peura DA. Gastrointestinal safety and tolerability of nonselective nonsteroidal anti-inflammatory agents and cyclooxygenase-2-selective inhibitors. Cleve Clin J Med. 2002;69Suppl 1:SI31–9.
  23. Dal Pan GJ. Acetaminophen: Background and Overview. 6/2009. Available at: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/DrugSafetyandRiskManagementAdvisoryCommittee/UCM175767.pdf Accessed 7/18/2012.
  24. Mills EJ, Wu P, Alberton M, et al. Low-dose Aspirin and Cancer Mortality: A Meta-analysis of Randomized Trials. Am J Med. 2012;125(6):560–7.
  25. Algra AM, Rothwell PM. Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol. 2012 May;13(5):518-27.
  26. Toussaint K, Yang XC, Zielinski MA, et al. What do we (not) know about how paracetamol (acetaminophen) works? J Clin Pharm Ther. 2010;35(6):617–38.
  27. Moyer AM, Fridley BL, Jenkins GD, et al. Acetaminophen-NAPQI Hepatotoxicity: A Cell Line Model System Genome-Wide Association Study. Toxicol Sci. 2011;120(1):33–41.
  28. James LP, Mayeux PR. Hinson JA. Acetaminophen-induced hepatotoxicity.Drug MetabDispos. 2003 Dec;31(12):1499-506.
  29. Hinson JA, Roberts DW, James LP. Mechanisms of acetaminophen-induced liver necrosis.HandbExpPharmacol. 2010;(196):369–405.
  30. Buckley N and Eddleston M. Paracetamol (acetaminophen) poisoning. ClinEvid (Online).2007;(14):1738–44.
  31. Ozkaya O, Genc G, Bek K, and Sullu Y.A case of acetaminophen (paracetamol) causing renal failure without liver damage in a child and review of literature.Ren Fail. 2010;32(9):1125–7
  32. Fitzgerald GA and Patrono C.The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med. 2001;345(6):433–42.
  33. Reiss AB, Anwar F, Chan ES, et al. Disruption of cholesterol efflux by coxib medications and inflammatory processes: link to increased cardiovascular risk. J Investig Med. 2009 Aug;57(6):695-702.
  34. Takahashi T, Takahashi T, et al. Proinflammatory cytokines detectable in synovial fluids from patients with temporomandibular disorders. Oral Surg Oral Med Oral Pathol Oral RadiolEndod 1998 Feb;85(2):135-41.
  35. Jeng KC, et al. Collagen induces cytokine production by synovial fluid mononuclear cells in rheumatoid arthritis. ImmunolLett 1995 Feb;45(1-2):13-7.
  36. Weir MR. Renal effects of nonselective NSAIDs and coxibs. Cleve Clin J Med. 2002;69Suppl 1:SI53-8.
  37. Gooch K, Culleton BF, Manns BJ, et al. NSAID use and progression of chronic kidney disease. Am J Med. 2007 Mar;120(3):280.e1-7.
  38. Sandoval-Acuña C, Lopez-Alarcón C, Aliaga ME, et al. Inhibition of mitochondrial complex I by various non-steroidal anti-inflammatory drugs and its protection by quercetin via a coenzyme Q-like action. ChemBiol Interact. 2012 Jul 30;199(1):18-28.
  39. Patel V, Fisher M, Voelker M, et al. Gastrointestinal effects of the addition of ascorbic Acid to aspirin. Pain Pract. 2012 Jul;12(6):476-84.
  40. van Leeuwen JS, Unlü B, Vermeulen NP, et al. Differential involvement of mitochondrial dysfunction, cytochrome P450 activity, and active transport in the toxicity of structurally related NSAIDs. ToxicolIn Vitro. 2012 Mar;26(2):197-205. Epub 2011 Nov 26.
  41. Watanabe T, Tanigawa T, Nadatani Y, et al. Mitochondrial disorders in NSAIDs-induced small bowel injury. J ClinBiochemNutr. 2011 Mar;48(2):117-21. Epub 2011 Feb 26.
  42. Doi H and Horie T. Salicylic acid-induced hepatotoxicity triggered by oxidative stress. ChemBiol Interact. 2010 Feb 12;183(3):363-8.
  43. O’Connor N, Dargan PI, and Jones AL. Hepatocellular damage from non-steroidal anti-inflammatory drugs. QJM. 2003 Nov;96(11):787-91.
  44. Li H, Hortmann M, Daiber A, et al. Cyclooxygenase 2-selective and nonselective nonsteroidal anti-inflammatory drugs induce oxidative stress by up-regulating vascular NADPH oxidases. J PharmacolExpTher. 2008 Sep;326(3):745-53.
  45. Bartolucci AA, Tendera M, Howard G. et al. Meta-analysis of multiple primary prevention trials of cardiovascular events using aspirin. Am J Cardiol. 2011 Jun 15;107(12):1796-801.
  46. Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP, Meade TW. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet. 2011 Jan 1;377(9759):31-41.
  47. Dolcet X, Llobet D, Pallares J, et al. NF-kB in development and progression of human cancer.Virchows Arch. 2005 May;446(5):475-82.
  48. Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst. 2002 Feb 20;94(4):252-66.
  49. Stark LA, Reid K, Sansom OJ, et al. Aspirin activates the NF-kappaBsignalling pathway and induces apoptosis in intestinal neoplasia in two in vivo models of human colorectal cancer. Carcinogenesis. 2007 May;28(5):968-76. Epub 2006 Nov 28.
  50. Schrör K. Pharmacology and cellular/molecular mechanisms of action of aspirin and non-aspirin NSAIDs incolorectal cancer.Best Pract Res ClinGastroenterol. 2011 Aug;25(4-5):473-84.
  51. Lanas A. Gastrointestinal bleeding associated with low-dose aspirin use: relevance and management in clinical practice. Expert Opin Drug Saf. 2011 Jan;10(1):45-54.
  52. García Rodríguez LA, Hernández-Díaz S, and de Abajo FJ. Association between aspirin and upper gastrointestinal complications: systematic review of epidemiologic studies. Br J ClinPharmacol. 2001 Nov;52(5):563-71.
  53. Derry S, Loke YK. Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. BMJ. 2000 Nov 11;321(7270):1183-7.
  54. De Berardis G, Lucisano G, D'Ettorre A, et al. Association of aspirin use with major bleeding in patients with and without diabetes. JAMA. 2012 Jun 6;307(21):2286-94.
  55. Smilkstein MJ, Knapp GL, Kulig KW, et al. Efficacy of oral N-acetylcysteine in the treatment of acetaminophen overdose. Analysis of the national multicenter study (1976 to 1985). N Engl J Med. 1988;319(24):1557–62.
  56. Johnson JB, John S, Laub DR. Pretreatment with alternate day modified fast will permit higher dose and frequency of cancer chemotherapy and better cure rates. Med Hypotheses. 2009;72(4):381–2.
  57. Harper JM, Salmon AB, Chang Y, et al. Stress resistance and aging: influence of genes and nutrition. Mech Ageing Dev. 2006;127(8):687–94.
  58. Hwang J. Diets with corn oil and/or low protein increase acute acetaminophen hepatotoxicity compared to diets with beef tallow in a rat model. Nutr Res Pract. 2009;3(2):95–101.
  59. Zhao L and Pickering G. Paracetamol metabolism and related genetic differences. Drug Metab Rev. 2011;43(1):41–52.
  60. Peterson K, McDonagh M, Thakurta S, et al. Drug Class Review: Nonsteroidal Antiinflammatory Drugs (NSAIDs): Final Update 4 Report. National Institute of Health (NIH) PubMed Health. Bethesda (MD): National Library of Medicine (US). Nov. 2010.
  61. Chen JT, Pucino F, Resman-Targoff BH. Celecoxib versus a Non-Selective NSAID Plus Proton-Pump Inhibitor: What Are the Considerations? J Pain Palliat Care Pharmacother. 2006;20(4):11-32.
  62. Roth SH. Nonsteroidal anti-inflammatory drug gastropathy: new avenues for safety. ClinInterv Aging. 2011;6:125–31.
  63. Wolf MS, King J, Jacobson K, et al. Risk of Unintentional Overdose with Non-Prescription Acetaminophen Products. J Gen Intern Med. 2012 May 26. [Epub ahead of print]
  64. Kobrinsky NL, Hartfield D, Horner H, et al. Treatment of advanced malignancies with high-dose acetaminophen and N-acetylcysteine rescue. Cancer Invest. 1996;14(3):202–10.
  65. Laine L, Kivitz AJ, Bello AE, et al. Double-blind randomized trials of single-tablet ibuprofen/high-dose famotidine vs. ibuprofen alone for reduction of gastric and duodenal ulcers.Am J Gastroenterol. 2012;107(3):379–86.
  66. Goldstein JL, Howard KB, Walton SM, et al. Impact of adherence to concomitant gastroprotective therapy on nonsteroidal-related gastroduodenal ulcer complications. ClinGastroenterolHepatol. 2006;4(11):1337–45.
  67. NIH MedlinePlus. Aspirin overdose. Available at: http://www.nlm.nih.gov/medlineplus/ency/article/002542.htm Accessed 7/20/2012A.
  68. Firdous AP, Sindhu ER, Kuttan R. Hepato-protective potential of carotenoid meso-zeaxanthin against paracetamol, CCl4 and ethanol induced toxicity. Indian J Exp Biol. 2011;49(1):44–9.
  69. Reagan-Shaw S, Nihal M, and Ahmad N. Dose translation from animal to human studies revisited. FASEB J. 2007;22(3):659–61
  70. Ghabril M, Chalasani N, Björnsson E. Drug-induced liver injury: a clinical update. CurrOpinGastroenterol. 2010;26(3):222–6.
  71. Iyanda A, Anetor J, Adeniyi F, et al. Effect of methionine on hepatic indices in male Wistar rat dosed to acetaminophen formulation. African Journal of Pharmacy and Pharmacology. 2010;4(9):653–7.
  72. Brown JM, Ball JG, Hogsett A, et al. Temporal study of acetaminophen (APAP) and S-adenosyl-L-methionine (SAMe) effects on subcellular hepatic SAMe levels and methionine adenosyltransferase (MAT) expression and activity. ToxicolApplPharmacol. 2010;247(1):1–9.
  73. Terneus MV, Brown JM, Carpenter AB, et al. Comparison of S-adenosyl-L-methionine (SAMe) and N-acetylcysteine (NAC) protective effects on hepatic damage when administered after acetaminophen overdose. Toxicology. 2008;244(1):25–34.
  74. Peterson FJ, Lindemann NJ, Duquette PH, et al. Potentiation of acute acetaminophen lethality by selenium and vitamin E deficiency in mice. J Nutr. 1992;122(1):74–81.
  75. Schnell RC, Park KS, Davies MH, et al. Protective effects of selenium on acetaminophen-induced hepatotoxicity in the rat.ToxicolApplPharmacol. 1988;95(1):1–11.
  76. Yalçin S, Bilgili A, Onbasilar I, et al. Synergistic action of sodium selenite and N-acetylcysteine in acetaminophen-induced liver damage. Hum ExpToxicol. 2008;27(5):425–9.
  77. Sindhu ER, Firdous AP, Preethi KC, et al. Carotenoid lutein protects rats from paracetamol-, carbon tetrachloride- and ethanol-induced hepatic damage. J Pharm Pharmacol. 2010;62(8):1054–60.
  78. Jamshidzadeh A, Baghban M, Azarpira N, et al. Effects of tomato extract on oxidative stress induced toxicity in different organs of rats. Food ChemToxicol. 2008;46(12):3612–5.
  79. Zahra T, Butt SA, Arshad, M. Effects of Beta Carotene on Liver Enzymes in Acetaminophen Treated Rats. Journal of Rawalpindi Medical College (JRMC). 2010;14(1):7–10.
  80. Abenavoli L, Capasso R, Milic N, et al. Milk thistle in liver diseases: past, present, future. Phytother Res. 2010;24(10):1423–32.
  81. Campos R, Garrido A, Guerra R, et al. Silybindihemisuccinate protects against glutathione depletion and lipid peroxidation induced by acetaminophen on rat liver. Planta Med. 1989;55(5):417–9.
  82. Hau DKP, Wong RSM, Cheng GYM, et al. Novel use of silymarin as delayed therapy for acetaminophen-induced acute hepatic injury.ForschKomplementmed. 2010;17(4):209–13.
  83. Cekmen M, Ilbey YO, Ozbek E, et al. Curcumin prevents oxidative renal damage induced by acetaminophen in rats. Food ChemToxicol. 2009;47(7):1480–4.
  84. Girish C, Koner BC, Jayanthi S, et al. Hepatoprotective activity of picroliv, curcumin and ellagic acid compared to silymarin on paracetamol induced liver toxicity in mice. FundamClinPharmacol. 2009;23(6):735–45.
  85. Kheradpezhouh E, Panjehshahin MR, Miri R, et al. Curcumin protects rats against acetaminophen-induced hepatorenal damages and shows synergistic activity with N-acetyl cysteine. European Journal of Pharmacology. 2010;628(1-3):274–81.
  86. Bagchi D, Ray SD, Bagchi M, et al. Mechanistic pathways of antioxidant cytoprotection by a novel IH636 grape seed proanthocyanidin extract. Indian J Exp Biol. 2002;40(6):717–26.
  87. Ray SD, Kumar MA, Bagchi D. A novel proanthocyanidin IH636 grape seed extract increases in vivo Bcl-XL expression and prevents acetaminophen-induced programmed and unprogrammed cell death in mouse liver. Arch. BiochemBiophys. 1999;369(1):42–58.
  88. Oz HS and Chen TS.Green-tea polyphenols downregulate cyclooxygenase and Bcl-2 activity in acetaminophen-induced hepatotoxicity. Dig Dis Sci. 2008;53(11):2980–8.
  89. Oz HS, McClain CJ, Nagasawa HT, et al. Diverse antioxidants protect against acetaminophen hepatotoxicity. J BiochemMolToxicol. 2004;18(6):361–8.
  90. Masubuchi Y, Sugiyama S, Horie T. Th1/Th2 cytokine balance as a determinant of acetaminophen-induced liver injury. ChemBiol Interact. 2009;179(2-3):273–9.
  91. Sener G, Toklu HZ, Sehirli AO, et al. Protective effects of resveratrol against acetaminophen-induced toxicity in mice.Hepatol Res. 2006b;35(1):62–8.
  92. Amimoto T, Matsura T, Koyama SY, et al. Acetaminophen-induced hepatic injury in mice: the role of lipid peroxidation and effects of pretreatment with coenzyme Q10 and alpha-tocopherol. Free RadicBiol Med. 1995;19(2):169–76.
  93. Fouad AA and Jresat I. Hepatoprotective effect of coenzyme Q10 in rats with acetaminophen toxicity. Environ. ToxicolPharmacol. 2012;33(2):158–67.
  94. Jonker D, Lee VS, Hargreaves RJ, et al. Comparison of the effects of ascorbylpalmitate and L-ascorbic acid on paracetamol-induced hepatotoxicity in the mouse.Toxicology. 1988;52(3):287–95.
  95. Abraham P. Mega dose of vitamin C augments the nephrotoxicity of paracetamol. Nephrology (Carlton). 2005;10(6):623–4.
  96. Nagalekshmi R, Menon A, Chandrasekharan DK, et al. Hepatoprotective activity of Andrographispaniculata and Swertiachirayita. Food ChemToxicol. 2011;49(12):3367–73.
  97. Visen PK, Shukla B, Patnaik GK, et al. Andrographolide protects rat hepatocytes against paracetamol-induced damage. J Ethnopharmacol. 1993;40(2):131–6.
  98. Sener G, Omurtag GZ, Sehirli O, et al. Protective effects of ginkgo biloba against acetaminophen-induced toxicity in mice.Mol Cell Biochem. 2006a;283(1-2):39–45.
  99. Hattori A, Yamada N, Nishikawa T, et al. Protective effect of ajoene on acetaminophen-induced hepatic injury in mice. BiosciBiotechnolBiochem. 2001;65(11):2555–7.
  100. Zhao C and Shichi H. Prevention of acetaminophen-induced cataract by a combination of diallyl disulfide and N-acetylcysteine.J OculPharmacolTher. 1998;14(4):345–55.
  101. Sumioka I, Matsura T, Yamada K. Therapeutic effect of S-allylmercaptocysteine on acetaminophen-induced liver injury in mice.European Journal of Pharmacology. 2001;433(2-3):177–85.
  102. Wang EJ, Li Y, Lin M, et al. Protective effects of garlic and related organosulfur compounds on acetaminophen-induced hepatotoxicity in mice. ToxicolApplPharmacol. 1996;136(1):146–54.
  103. Matsura T, Nishida T, Togawa A, et al. Mechanisms of protection by melatonin against acetaminophen-induced liver injury in mice. J Pineal Res. 2006;41(3):211–9.
  104. Kanno SI, Tomizawa A, Hiura T, et al. Melatonin protects on toxicity by acetaminophen but not on pharmacological effects in mice. Biol Pharm Bull. 2006;29(3):472–6.
  105. Ilbey YO, Ozbek E, Cekmen M, et al. Melatonin prevents acetaminophen-induced nephrotoxicity in rats. IntUrolNephrol. 2009;41(3):695–702.
  106. Omatsu T, Naito Y, Handa O, et al. Reactive oxygen species-quenching and anti-apoptotic effect of polaprezinc on indomethacin-induced small intestinal epithelial cell injury. J Gastroenterol. 2010;45(7):692–702.
  107. Matsukura T, Tanaka H. Applicability of zinc complex of L-carnosine for medical use.Biochemistry (Mosc). 2000 Jul;65(7):817-23.
  108. Cho CH, Luk CT, Ogle CW. The membrane-stabilizing action of zinc carnosine (Z-103) in stress-induced gastric ulceration in rats. Life Sci. 1991;49(23):L189-94.
  109. Furuta S, Toyama S, Miwa M, et al. Residence time of polaprezinc (zinc L-carnosine complex) in the rat stomach and adhesiveness to ulcerous sites. Jpn J Pharmacol. 1995 Apr;67(4):271-8.
  110. Mahmood A, FitzGerald AJ, Marchbank T, et al. Zinc carnosine, a health food supplement that stabilises small bowel integrity and stimulates gut repair processes. Gut. 2007;56(2):168–75.
  111. Wittschier N, Faller G, Hensel A. Aqueous extracts and polysaccharides from liquorice roots (Glycyrrhizaglabra L.) inhibit adhesion of Helicobacter pylori to human gastric mucosa. J Ethnopharmacol. 2009 Sep 7;125(2):218-23. Epub 2009 Jul 14.
  112. AlyAM, Al-Alousi L, Salem HA. Licorice: a possible anti-inflammatory and anti-ulcer drug. AAPS PharmSciTech. 2005;6(1):E74–82.
  113. Sancar M, Hantash T, Okuyan B, et al. Comparative effectiveness of Glycyrrhizaglabra vs. omeprazole and misoprostol for the treatment of aspirin-induced gastric ulcers. African Journal of Pharmacy and Pharmacology. 2009;3(12):615–20.
  114. Bennett A, Clark-Wibberley T, Stamford IF, Wright JE. Aspirin-induced gastric mucosal damage in rats: cimetidine and deglycyrrhizinatedliquorice together give greater protection than low doses of either drug alone. J Pharm Pharmacol. 1980 Feb;32(2):151.
  115. Das SK, Das V, Gulati AK, Singh VP.Deglycyrrhizinatedliquorice in aphthous ulcers.J Assoc Physicians India. 1989 Oct;37(10):647.
  116. Anonymous.Boswelliaserrata.Monograph.Altern Med Rev. 2008;13(2):165–7
  117. Singh S, Khajuria A, Taneja, SC, et al. The gastric ulcer protective effect of boswellic acids, a leukotriene inhibitor from Boswelliaserrata, in rats.Phytomedicine. 2008;15(6-7):408–15
  118. Maity P, Bindu S, Dey S, et al. Melatonin reduces indomethacin-induced gastric mucosal cell apoptosis by preventing mitochondrial oxidative stress and the activation of mitochondrial pathway of apoptosis. J Pineal Res. 2009 Apr;46(3):314-23.
  119. Sivalingam N, Basivireddy J, Balasubramanian KA, et al. Curcumin attenuates indomethacin-induced oxidative stress and mitochondrial dysfunction. Arch Toxicol. 2008 Jul;82(7):471-81.